GSK signs broad collaboration with Theravance
GlaxoSmithKline PLC and Theravance (developing drugs in several therapeutic areas), partners in the development of respiratory drugs since January 2003, have entered another agreement. Under terms of the new deal, which they are calling "Beyond Advair," GSK gets an exclusive worldwide development and marketing option to any of Theravance's current or future drug candidates through August 2007.
- Includes Contract
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.